El-Naggar, Abdel Rahman <br/><br/>
The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients.  [electronic resource] 

 -  Journal of cardiovascular pharmacology and therapeutics  05 2019 
 - 254-261 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1940-4034 
<br/><br/><label>Standard No.: </label>10.1177/1074248418817345  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antihypertensive Agents--adverse effects<br/>Biomarkers--blood<br/>Blood Pressure--drug effects<br/>Captopril--adverse effects<br/>Diabetes Mellitus, Type 2--blood<br/>Dipeptidyl-Peptidase IV Inhibitors--adverse effects<br/>Egypt<br/>Female<br/>Glycated Hemoglobin--metabolism<br/>Humans<br/>Hypertension--blood<br/>Insulin Resistance<br/>Lipids--blood<br/>Male<br/>Metformin--adverse effects<br/>Middle Aged<br/>Prospective Studies<br/>Time Factors<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--blood<br/>Vildagliptin--adverse effects